fr | en

Séparés par des virgules

Frederic LagarceBiopharmacie

    • Départements d'Enseignement SANTE - Dép. d'Enseignement Pharmacie SANTE
    • 0241226740
    • 28 rue Roger Amsler - 49045 - ANGERS CEDEX 01
    • Biopharmacie

    Afficher UFR de Médecine sur une carte plus grande
    • Inserm U1066 Mint CNRS 6021

    • 0241353544


    Pharmacotechnie & Biopharmacie

    Thèmes de recherche

    Frederic Lagarce received his PhD in 2004, and is Professor of Pharmaceutical Technology and Biopharmaceutics since 2012 in the University of Angers in France. Being also Hospital Pharmacist, his research are translational (from bench to bedside) and mainly focused on cancer therapy, especially on bioavailability enhancement by playing on the interactions between the drug products (mainly nanosystems) and the living tissues. This field involves biological barrier crossing studies but also stability assessment of the active moieties and overcoming the acquired resistances to drugs. In hospital he is in charge of the pharmaceutical technology and quality control unit. Finding new answers to medical needs using innovative drug formulations is what drives him every day to work.



    Je m'attache à développer des nouvelles formulations de médicaments issus des micro et des nanotechnologies afin de faciliter le passage des barrières biologique et le ciblage tumoral. Je travaille en particulier sur la voie orale avec une équipe de 2-4 thésards et plusieurs étudiants de 3ème cycle français et étrangers. Mes travaux sont financées par la Ligue contre le Cancer et des projets européens.



    - Pharmacist with specialization in hospital Pharmacy, University of Angers, 2000.

    - PhD in Pharmacy, with distinction, University of Angers, 2004.

    (Title : ‘Development and evaluation of a sustained release biodegradable dosage form intended for chronic therapy via the intrathecal route: Application to baclofen-loaded microspheres aimed at severe spasticity treatment' Co-ordinator: Pr JP. Benoit).

    - Accreditation to supervise research, University of  Angers, 2010.



    - Professor, Pharmaceutical Technology & Biopharmacy, University of Angers 2008 to present.



    -  Chief Hospital Pharmacist, University Hospital of Angers



    Evaluation with in vivo or in vitro models of the biopharmaceutical performances of micromedicine or nanomedicine. The primary field of interest are the oral route and anticancer chemotherapy with colloidal carriers. Pharmacokinetics, Pharmacodynamics and toxicological studies are important side research fields. The research is currently focused on lipid nanocapsules optimization for crossing biological barriers.



    Biopharmacy, in vitro models, cell culture, Pharmacokinetics, PKPD, Nanomedicine, cancer, oral delivery, lung delivery, brain delivery


    • F. Lagarce, O. Cruaud, C. Deuschel, M. Bayssas, G. Griffon-Etienne, and J.P. Benoit. Oxaliplatin loaded PLAGA microspheres: design of specific release profiles. Int J Pharm. 242:243-246 (2002).
    • F. Lagarce and J.P. Benoit. Sustained release formulations for spinal drug delivery. J Drug Deliv Sci Tech 14:331-343 (2004).
    • F. Lagarce, N. Faisant, J.C. Desfontis, L. Marescaux, F. Gautier, D. Holopherne, M.C. Rousselet, P. Menei, and J.P. Benoit. Biopharmaceutics of intrathecal baclofen-loaded microparticles in a goat model. Int J Pharm. 298:68-79 (2005).
    • F. Lagarce, N. Faisant, J.C. Desfontis, L. Marescaux, F. Gautier, J. Richard, P. Menei, and J.P. Benoit. Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 61:171-180 (2005).
    • F. Lagarce, P. Renaud, N. Faisant, G. Nicolas, A. Cailleux, J. Richard, P. Menei, and J.P. Benoit. Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model. Eur J Pharm Biopharm. 59:449-459 (2005).
    • F. Lagarce, E. Garcion, N. Faisant, O. Thomas, P. Kanaujia, P. Menei, and J.P. Benoit. Development and characterization of interleukin-18-loaded biodegradable microspheres. Int J Pharm. 314:179-188 (2006).
    • S. Peltier, J.M. Oger, F. Lagarce, W. Couet, and J.P. Benoit. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res. 23:1243-1250 (2006).
    • Sapin, E. Garcion, A. Clavreul, F. Lagarce, J.P. Benoit, and P. Menei. Development of new polymer-based particulate systems for anti-glioma vaccination. Int J Pharm. 309:1-5 (2006).
    • J. Hureaux, F. Lagarce, F. Gagnadoux, A. Clavreul, J.P. Benoit, and T. Urban. The adaptation of lipid nanocapsule formulations for blood administration in animals. Int J Pharm. 379:266-269 (2009).
    • J. Hureaux, F. Lagarce, F. Gagnadoux, L. Vecellio, A. Clavreul, E. Roger, M. Kempf, J.L. Racineux, P. Diot, J.P. Benoit, and T. Urban. Lipid nanocapsules: Ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm 73(2):239-46  (2009).
    • E. Roger, F. Lagarce, and J.P. Benoit. The gastrointestinal stability of lipid nanocapsules. Int J Pharm. 379:260-265 (2009).
    • E. Roger, F. Lagarce, E. Garcion, and J.P. Benoit. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release 140(2): 174-181 (2009).
    • E. Roger, F. Lagarce, E. Garcion, and J.P. Benoit. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery, Nanomedicine (London, UK), 5 (2): 287-306 (2010)
    • J. Hureaux, F. Lagarce, F. Gagnadoux, MC. Rousselet, V. Moal, T. Urban, JP. Benoit. Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice. Pharmaceutical research 27(3) 421-430 (2010).
    • E. Roger, F. Lagarce, E. Garcion, and J.P. Benoit. Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur J Pharm Sci. 40(5), 422-429. (2010)
    • E. Roger, F. Lagarce, J.P. Benoit. Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm, 79(1): 181-8 (2011)
    • A. Ramadan, F. Lagarce, A. tessier-Marteau, O. Thomas, P. Legras, L. Macchi, P. Saulnier, JP. Benoit. Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. Int J Nanomedicine, 6, 2941-2951 (2011)
    • B. Saliou, O. Thomas, N. Lautram, A. Clavreul, J. Hureaux, T. Urban, JP Benoit, F. Lagarce. Development and in vitro evaluation of a novel lipid nanocapsules formulation of etoposide. Eur J Pharm Sci, 50(2), 172-180. (2013)
    • AC. Groo, P. Saulnier, JC. Gimel, J. Gravier, C. Ailhas, JP. Benoit, F. Lagarce. Fate of Paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. Int J Nanomédicine, 8, 4291-302. (2013)
    • O. Thomas, F. Lagarce. Lipid nanocapsules: a nanocarrier suitable for scale-up process. J Drug Deliv Sci Tech, 23 (6) 555-559. (2013)
    • P. Bourget, A. Amin, F. Vidal, C. Merlette, F. Lagarce, Comparison of Raman spectroscopy vs. high performance liquid chromatography for quality control of complex therapeutic objects: Model of elastomeric portable pumps filled with a fluorouracil solution. J Pharm Biomed Anal, 91, 176-184. (2014)
    • AC. Groo, K. Mircheva, J. Bejaud, C. Ailhas, I. Panaiotov, P. Saulnier, Z. Ivanova, F. Lagarce, Development of 2D and 3D Mucus Models and Their Interactions with Mucus Penetrating Paclitaxel Loaded Lipid Nanocapsules. Pharm Res, 31(7), 1753-1765 (2014)
    • K. Messaoudi, P. Saulnier, K. Boesen, JP. Benoit, F. Lagarce. Anti-EGR siRNA carried by chitosan transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide. Int J Nanomedecine, 9, 1479-1490 (2014)
    • AC Groo, F. Lagarce, Mucus models to evaluate nanomedicines for diffusion, Drug Discovery Today, 19 (8), 1097-1108 (2014)
    • A.C. Groo, M. Bossiere, L. Trichard, P. Legras, JP. Benoit, F. Lagarce. In vivo evaluation of Paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor, Nanomedicine UK,10(4), 589-601 (2015)
    • F. Danhier, K. Messaoudi, L. Lemaire, JP. Benoit, F. Lagarce. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation. International journal of Pharmaceutics, 481 (1-2), 154-163 (2015)
    • K. Messaoudi, A. Clavreul, F. Lagarce. Toward an effective strategy in glioblastoma treatment (Part I): resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide, Drug Discovery Today, 20(7), 899-905 (2015)
    • K. Messaoudi, A. Clavreul, F. Lagarce. Toward an effective strategy in glioblastoma treatment (Part II): RNA Interference as a promising way to sensibilize glioblastomas to Temozolomide, Drug Discovery Today, 20(6) 772-779 (2015)
    • H. Malhaire, F. Lagarce. Is the translational approach becoming a reality in nanomedicine? European journal of Nanomedicine, 7(2), 79-84 (2015)
    • K. Messaoudi, F. Danhier, A. Clavreul, P. Saulnier, JP. Benoit, F. Lagarce. Combined silencing expression of MGMT with EGFR or Galectin-1 enhances the sensitivity of glioblastoma to temozolomide, European journal of nanomedicine, 7(2), 97-107 (2015)
    • F. Lagarce. Nanomedicine: are we lost in translation ?, European journal of nanomedicine, 7(2), 77-78 (2015)
    • S. Vrignaud, T. Briot, A. Launay, M. Kempf, F. Lagarce, Design and stability study of a paediatric oral solution of methotrexate 2 mg/ml, International Journal of Pharmaceutics, 487(1-2), 270-273 (2015)
    • T. Briot, S.Vriganud, F. Lagarce, Stability of micafungin sodium solutions at different concentrations in glass bottles and syringes, International Journal of Pharmaceutics, 492(1-2), 137-40 (2015)
    • F. Lagarce, C. Passirani, Nucleic-acid delivery using lipid nanocapsules, Current Pharmaceutical Biotechnology, 17(8), 723-727 (2016).
    • C. Bastiancich, K. Vanvarenberg, B. Ucakar, M. Pitorre, G. Bastiat, F. Lagarce, V. Preat, F. Danhier, Lauroyl-gemcitabine-loaded lipid nanocapsules hydrogel for the treatment of Glioblastoma, J Cont Release, 225, 283-293 (2016)
    • H. Malhaire, JC. Gimel, E. Roger, JP. Benoit, F. Lagarce, How to design the surface of peptide-loaded nanoparticles forefficient oral bioavailability?, Advanced Drug Delivery Reviews, 106, 320-336 (2016)
    • G. Bougueon, F. Lagarce, L. Martin, H. Pailhores, G. Bastiat, S. Vrignaud, Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas, Int J Pharm, 509, 279-284 (2016)
    • T. Briot, C. Truffaut, L Le Quay, A Lebreton, F. Lagarce. Stability of Reconstituted and Diluted Mitomycin C Solutions in Polypropylene Syringes and Glass Vials, Pharmaceutical Technology in Hospital Pharmacy, 1(2), 83-89 (2016)
    • P.A. Billat, E. Roger, S. Faure, F. Lagarce. Models for drug absorption from the small intestine: Where are we and where are we going ?, Drug discovery today, In Press
    • G. Leroux, H. Moche, A. Nieto, F. Neslany, J.P. Benoit, F. Lagarce. Cytotoxicity and genotoxicity of lipid nanocapsules, Toxicology In vitro, 41, 189-199 (2017)
    • F. lagarce. Centrally prepared cytotoxic drugs : what is the purpose of their quality control ? Pharmaceutical Technology in Hospital Pharmacy, 2 (1), 29-33 (2017)
    • C. Bastiancich, J. Bianco, K. Vanvarenberg, B. Ucakar, N. Joudiou, B. Gallez, G. Bastiat, F. Lagarce, V. Préat, F. Danhier. Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection, Journal of controlled release, 264, 45-54 (2017)
    • J. Hureaux, F. Lacoeuille, F. Lagarce, MC. Rousselet, A Contini, P. Saulnier, JP. Benoit, T. Urban. Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats, International journal of Nanomedicine, 12, 8159-8170 (2017)
    • T. Briot, E. Roger, N. Lautram, A. Verger, A. Clavreul, F. Lagarce. Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia, International journal of Nanomedicine, 12, 8427-8442 (2017)
    • C. Bastiancich, G. Bastiat, F. Lagarce. Gemcitabine and glioblastoma: challenges and current perspectives, drug discovery today, In press to be published in Feb 2018
    • Chappe, S. Vrignaud, L. De Gentile, G. Legrand, F. Lagarce, Y. Le Govic. Successful treatment of a recurrent Aspergillus niger otomycosis with mocal application of voriconazole, Journal of Mycol Med, Jun;28(2):396-398 (2018)
    • Briot, E. Roger, S. Thepot, F. Lagarce. Advances in treatment formulations for acute myeloid leukemia, in press, Drug Discovery Today, Dec;23(12):1936-1949 (2018)
    • E Gautier, J Saillard, C Deshayes, S Vrignaud, F Lagarce, T Briot. Stability of a 50 mg/mL Ceftazidime Eye-Drops Formulation. Pharmaceutical Technology in Hospital Pharmacy 3 (4), 219-226 (2018)
    • Bastiancich, L. Lemaire, J. Bianco , F. Franconi, F. Danhier , V. Préat , G. Bastiat, F.Lagarce. Evaluation of Lauroyl-gemcitabine loaded hydrogel efficacy in glioblastoma rat models, Nanomedicine (Lond), Aug;13(16):1999-2013 (2018)
    • Briot, E. Roger, N. Bou Haidar, J. Bejaud, N. Lautram, C. Guillet, S. Thépot, S. Legeay, F. Lagarce. Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity. Int J Nanomedicine. Mar 26;14:2091-2102 (2019)
    • Sautou, F. Lagarce. Methods for the Study of Physical and Chemical Stability and Container-Content Interactions. Pharm Tech Hosp Pharmacy, 4(2) 95-97 (2019)Lagarce. Nanomedicines promises and reality. editorial, drug discovery today. Mar;25(3):473-474 (2020)
    • Lebreton, B. Bourcier, K. Cosson, F. Lagarce, L. Spiesser-Robelet, S.Vrignaud, New liquid oral formulations of hydroxychloroquine: a physicochemical stability study. Pharmaceutical Technology in Hospital Pharmacy ; 6(1) (2021)
    • C. Annweiler, Lagarce, N. Lerolle, Serving and studying during COVID-19 pandemic. Clin Teach. Jun;18(3):224-225. (2021)
    • Lebreton, S. Legeay, P. Saulnier, F. Lagarce, Specificity of pharmacokinetic modeling of nanomedicines. Drug Discov Today. Oct;26(10):2259-2268 (2021)
    • Spiesser-Robelet, I. Baglin, F. Moal, F. Lagarce, M Eveillard, Engagement of students enrolled in fifth year of pharmacy studies in their academic or salaried pharmaceutical activities during the first period of lockout due to the COVID-19 pandemic (16th March-11th May 2020). Ann Pharm Fr. Jan;80(1):101-111 (2022)
    • Bourcier, F. Lagarce, V. Lebreton. Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization. J Pharm Biomed Anal. Feb 20;210:114543 (2022)
    • Lebreton, N. Kaeokhamloed, A. Vasylaki, G. Hilairet, A. Mellinger, J. Béjaud, P. Saulnier, F. Lagarce, F. Gattacceca F, S. Legeay, E. Roger. Pharmacokinetics of intect lipid nanocapsules using new quantitative FRET Technique. J Control Release. 351:681-691 (2022)
    • Lebreton V, Legeay S, Vasylaki A, Lagarce F, Saulnier P. Protein corona formation on lipidic nanocapsules: influence of the interfacial PEG repartition. Eur J Pharm Sci. 189 (2023)
  • Courriel : frederic.lagarce @
Modifier ma fiche